Literature DB >> 33670031

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer.

Josip Maleš1,2, Hrvoje Mihalj1,2, Anamarija Šestak2, Kristina Kralik3, Martina Smolić4,5.   

Abstract

Background and
Objectives: Increased osteopontin (OPN) concentrations in the plasma of patients with head and neck squamous cancer (HNSCC) have diagnostic significance, and it can indicate more aggressive biological behavior of cancer. The aim of this study was to determine OPN levels in patients with HNSCC of different primary locations and to assess its prognostic significance in metastasis development. Materials and
Methods: This cohort study included 45 patients (41 male and 4 female patients) with HNSCC with different primary localization of head and neck. All patients underwent surgery-neck dissection. All patients were categorized according to the histological findings of the resected material and tumor-node-metastasis (TNM) classification system. After surgery, N categories were determined on the basis of histological features of resected material.
Results: The histological findings of our patients showed: N0 in 11 patients, N1 in 8 patients, N2a in 4 patients, N2b in 14 patients and N2c in 8 patients. Plasma OPN values in all study participants ranged from 2.24 to 109.10 ng/mL. OPN levels in plasma of patients with negative nodes compared to the group of patients with positive nodes in the neck differed significantly (16.89 ng/mL to 34.08 ng/mL, respectively; p = 0.03). There were significantly lower OPN plasma levels in the group of subjects with histologically positive one lymph node in the neck (N1) compared to the group of patients with N2b histologically positive findings of resected neck material (10.4 ng/mL to 43.9 ng/mL, respectively; p = 0.02). Conclusions: The results have shown that growing N degrees of positive neck nodes classification were accompanied by growing values of plasma osteopontin. Osteopontin might be important for the development of neck metastases.

Entities:  

Keywords:  neck metastases; osteopontin; squamous cancer

Mesh:

Substances:

Year:  2021        PMID: 33670031      PMCID: PMC7926686          DOI: 10.3390/medicina57020185

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  21 in total

1.  Clinical significance of elevated osteopontin levels in head and neck cancer patients.

Authors:  Mayumi Eto; Satoru Kodama; Nozomi Nomi; Naoki Uemura; Masashi Suzuki
Journal:  Auris Nasus Larynx       Date:  2007-01-24       Impact factor: 1.863

2.  Osteopontin, osteocalcin and OB-cadherin expression in Synthetic nanohydroxyapatite vs bovine hydroxyapatite cultured Osteoblastic-like cells.

Authors:  A Santarelli; M Mascitti; G Orsini; L Memè; R Rocchetti; P Tiriduzzi; F Sampalmieri; A Putignano; M Procaccini; L Lo Muzio; F Bambini
Journal:  J Biol Regul Homeost Agents       Date:  2014 Jul-Sep       Impact factor: 1.711

3.  Differential osteopontin expression in lung cancer.

Authors:  J Zhang; K Takahashi; F Takahashi; K Shimizu; F Ohshita; Y Kameda; K Maeda; K Nishio; Y Fukuchi
Journal:  Cancer Lett       Date:  2001-10-10       Impact factor: 8.679

4.  Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.

Authors:  Jens Overgaard; Jesper Grau Eriksen; Marianne Nordsmark; Jan Alsner; Michael R Horsman
Journal:  Lancet Oncol       Date:  2005-08-27       Impact factor: 41.316

5.  Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma.

Authors:  Chih-Yen Chien; Chih-Ying Su; Hui-Ching Chuang; Fu-Min Fang; Hsuan-Ying Huang; Chang-Han Chen; Ching-Mei Chen; Chao-Cheng Huang
Journal:  Oral Oncol       Date:  2009-02-11       Impact factor: 5.337

6.  [Correlation of osteopontin expression and laryngeal squamous cell carcinoma infiltration and metastasis].

Authors: 
Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2015-09

7.  Clinical significance of osteopontin expression in T1 and T2 tongue cancers.

Authors:  Chih-Yen Chien; Chih-Ying Su; Hui-Ching Chuang; Fu-Min Fang; Hsuan-Ying Huang; Ching-Mei Chen; Chang-Han Chen; Chao-Cheng Huang
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

8.  Immunohistochemical study of osteopontin in oral squamous cell carcinoma allied to fractal dimension.

Authors:  G D'Addazio; L Artese; T Traini; C Rubini; S Caputi; B Sinjari
Journal:  J Biol Regul Homeost Agents       Date:  2018 Jul-Aug       Impact factor: 1.711

9.  Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.

Authors:  Alfonso Cristaudo; Rudy Foddis; Alessandra Bonotti; Silvia Simonini; Agnese Vivaldi; Giovanni Guglielmi; Nicolino Ambrosino; Pier Aldo Canessa; Antonio Chella; Marco Lucchi; Alfredo Mussi; Luciano Mutti
Journal:  Int J Biol Markers       Date:  2010 Jul-Sep       Impact factor: 3.248

10.  Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer.

Authors:  Catharina M L Zegers; Frank J P Hoebers; Wouter van Elmpt; Judith A Bons; Michel C Öllers; Esther G C Troost; Daniëlle Eekers; Leo Balmaekers; Marlies Arts-Pechtold; Felix M Mottaghy; Philippe Lambin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-01       Impact factor: 9.236

View more
  2 in total

1.  Establishment and Analysis of an Individualized Immune-Related Gene Signature for the Prognosis of Gastric Cancer.

Authors:  Mengying Li; Wei Cao; Bingqian Huang; Zhipeng Zhu; Yaxin Chen; Jiawei Zhang; Guodong Cao; Bo Chen
Journal:  Front Surg       Date:  2022-01-31

2.  A Four-Gene Signature Associated with Radioresistance in Head and Neck Squamous Cell Carcinoma Identified by Text Mining and Data Analysis.

Authors:  Yongqian Zhang; Hongmin Wang; Feifei Wang; Wenhua Ma; Na Li; Changwen Bo; YingChun Zhao; Li He; Ming Liu
Journal:  Comput Math Methods Med       Date:  2022-09-27       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.